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Abstract
Background: The relationships between the expression of CD133, Ki-67 and prognosis in gastric adenocarcinoma are 
unknown and needs exploring.
Methods: The samples of gastric adenocarcinoma from 336 Chinese patients with follow-up were analyzed for CD133 
and Ki-67 protein expressions by immunohistochemical method.
Results: CD133 was expressed in up to 57.4% (193/336) of this group of gastric carcinoma. The expression of CD133 
was significantly higher in carcinoma than in normal (P = 0.0001) and dysplastic mucosas (P = 0.004). CD133 was 
positive corresponded with the tumour size, grade, infiltrative depth and clinical stage (all P < 0.05). The overall mean 
survival time of the patients with CD133 positive expression was shorter than that of patients with negative expression 
(P = 0.0001). The expression of CD133 has a positive correlation with that of Ki-67 (r = 0.188, P = 0.001) in gastric 
adenocarcinoma. CD133 was an independent prognostic indicator. (P = 0.0001).
Conclusions: It is suggested that CD133 may play an important role in the evolution of gastric adenocarcinoma and 
should be considered as a potential marker for the prognosis.
Background
Gastric cancer is one of the most aggressive malignan-
cies, with an extremely poor prognosis, and is the second
leading cause of cancer death worldwide [1]. The preva-
lence of gastric cancer in China is amongst the highest in
the world, along with Japan and Korea. Lowest rates are
associated with the more developed regions such as
Northern Europe and North America. By the time the
patient is clinically diagnosed, the gastric cancer has
often grown beyond the limits of curative resection. This
reality has raised therapeutic problems, and new early
diagnostic tools and therapeutic techniques concerning
this disease are urgently needed. CD133 is a pentaspan
transmembrane glycoprotein, with a molecular weight of
120 kDa [2]. Although it was initially considered to be
one marker of hematopoietic stem cells, CD133 mRNA
transcript could also be found in normal non-lymphoid
hematopoietic tissue [2]. CD133 is overexpressed in vari-
ous solid tumours [3-7], including colon cancer and glio-
blastoma [8,9]. O'Brien et al.[9] performed purification of
CD133-positive cells in colon carcinoma by flow cytome-
try and transplanted them into mice, leading to the for-
mation of tumours in renal subcapsule, suggesting that
CD133 may be a cancer stem cell marker for colon carci-
noma. Recently, Smith and colleagues have shown that a
moderate to high percentage of gastric cancer tumor
samples have CD133 expression with moderate to strong
membranous and apical expression. No significant asso-
ciation with tumor stage or grade was identified but this
conclusion was based on a limited number of cases stud-
ied.
They identified CD133 as a potential therapeutic target
for antibody-drug conjugates in gastric cancer [10], rais-
ing the possibility of molecular targeting therapy in this
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most aggressive malignancy. CD133 expression as a prog-
nostic marker has been found in colorectal cancer [11-18]
and brain tumours [19-21] but it is still unclear if CD133
can be used as a prognostic marker in pancreatic cancer
[22], ovarian cancer [23], hepatocellular cancer [24,25]
and non-small cell lung carcinoma [26]. Whether CD133
is a prognostic marker in gastric cancer is still unclear
since to date no extensive study has been performed cor-
relating CD133 expression with clinicopathological fea-
tures and prognosis. Ki-67 is a well-recognized nuclear
antigen-specific marker associated with cellular prolifera-
tion, and primarily used to judge the activity of prolifera-
tion. The relationship between CD133 and Ki-67 in
gastric cancer has not yet been investigated. We per-
formed an immunohistochemical study to investigate the
possible role of the expression of CD133 in clinicopathol-
ogy and prognosis, as well as the relationship between
CD133 and Ki-67 in 336 cases of gastric adenocarcinoma.
It is hoped that the study will give information on the
pathogenesis of this disease.
Methods
Biopsy Specimens
Paraffin embedded sections of 336 gastric adenocarcino-
mas with 58 adjacent dysplastic mucosas and 60 distal
normal gastric tissues were obtained from the Depart-
ment of Pathology, Chinese People's Liberation Army
(PLA) General Hospital (Beijing, China). Ethical approval
for this study was not required by our institution as the
experiments carried out did not relate to patient's pri-
vacy, impairment or treatment. The age of the patients
ranged from 18-85 years, with an average of 58.1 years.
Two hundred seventy-four were men and 62 were
women. Seventeen were at grade 1, 65 at grade 2 and 254
at grade 3, according to histological grading. Sixty-six
were at stage I, 77 at stage II, 147 at stage III and 46 at
stage IV, according to clinical staging of TNM, respec-
tively. Lymphatic metastasis in regional nodes at opera-
tion was confirmed in 225 cancers of this study.
Immunohistochemistry
All samples were fixed in 10% buffered formalin and
embedded in paraffin. Sections were cut 4 μM thick from
wax blocks, mounted on to APES-coated glass slides.
Slides were deparaffinized in xylene twice for 10 minutes,
rehydrated through graded ethanols to distilled water
before incubation for 15 minutes with 3% hydrogen per-
oxidase-methanol to inhibit endogenous peroxidase
activity, and heated in 0.01 M citrate buffer (pH 6.0) in a
microwave oven for 5 minutes at 100°C; after boiling for
antigen retrieval. Then the slides were taken out of
microwave oven and cooled to room temperature for 30
minutes. After incubating for 15 minutes in a blocking
solution containing 10% normal goat serum in PBS, sec-
tions were incubated at 4°C overnight in a humidified
chamber with rabbit polyclonal antibody to human
CD133 (Abcam Inc., Cambridge, MA, USA) diluted 1:100
in blocking solution and mouse mononal antibody to
human Ki-67 (Zymed Laboratories Inc., South San Fran-
cisco, CA) diluted 1:100 in blocking solution. The sec-
tions were rinsed in PBS and incubated for 20 minutes
with Polyperoxidase-anti-mouse/rabbit IgG (Zymed).
After washing in PBS, 3,3'-Diaminobenzidine was used as
the chromogen. Slides were counterstained for 3 minutes
with hematoxylin solution. Brain medulloblastoma tissue
was used as a positive control, whereas the primary anti-
body was replaced by 0.01 M PBS as a negative control.
Evaluation of score
In scoring expression of CD133 and Ki-67 protein, both
the extent and intensity of immunopositivity were con-
sidered, according to Hao et al [27]. The intensity of posi-
tivity was scored as follows: 0, negative; 1, weak; 2,
moderate; 3, strong. The extent of positivity was scored
according to the percentage of cells showing positive
staining: 0, < 5%; 1, > 5-25%; 2, > 25-50%; 3, > 50-75%; 4, >
75% of the cells in the respective lesions. The final score
was determined by multiplying the intensity of positivity
and the extent of positivity scores, yielding a range from 0
to 12. The expression for CD133 and Ki-67 was consid-
ered positive when the scores were ≥5.
Statistical Analysis
Fisher's exact test (two sided), Pearson Chi's square test
for trends in proportions, Spearman's correlation coeffi-
cient test, and Kaplan-Meier's method with log rank test
or Cox Regression method for univariate or multivariate
overall survival analysis were used to assess the associa-
tions between expression of CD133 or Ki-67 and clinico-
pathological indices by SPSS 15.0 for Windows (Chicago,
IL). A  P < 0.05 was considered statistically significant.
Results
Expression of CD133 in gastric adenocarcinoma
CD133 protein was expressed positively in 57.4% (193 out
of 336) of gastric adenocarcinoma, 36.2% (21 out of 58) of
adjacent dysplastic epithelia and 28.3% (17 out of 60) of
distal normal mucosa. The localization of CD133 protein
was primarily in the membrane and cytoplasm of cancer
cells (Figure 1). In well-differentiated adenocarcinoma,
CD133 protein was found predominantly around the
lumen of cancerous gland (Figure 2). A very significant
difference was found in the expression of CD133 protein
between gastric adenocarcinoma and normal mucosa or
adjacent dysplastic tissues (P = 0.0001; P = 0.004). ThereZhao et al. BMC Cancer 2010, 10:218
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was no difference in CD133 expression between normal
mucosa and adjacent dysplastic mucosa (P = 0.432).
The association between expression of CD133 and 
clinicopathological features
The gastric adenocarcinoma with positive expression of
CD133 was 41.2% (7 out of 17) at grade 1, 46.2% (30 out
of 65) at grade 2 and 61.4% (156 out of 254) at grade 3,
respectively, thus the association between expression of
CD133 and histological grade was statistically significant
(P = 0.032) (Table 1). With respect to the TNM tumor
staging adenocarcinoma with positive expression of
CD133 was 28.8% (19 out of 66) at stage I, 49.4% (38 out
of 77) at stage II, 66.7% (98 out of 147) at stage III and
82.6% (38 out of 46) at stage IV, respectively. Statistically,
the positive expression of CD133 correlated with the
more advanced clinical stage (P = 0.0001). Expression of
CD133 was also found to positively correlate with the
tumour size (P = 0.0001), invasive depth (Figure 3; P =
0.0001) and metastasis in the regional lymph nodes (P =
0.0001), but not with the age of the patients (P = 0.434)
(Table 1). Follow-up data showed that a significantly
decreasing trend in 5-year survival was observed in
patients with the expression of CD133 (P = 0.0001) (Table
1). There was also a significant difference in the overall
mean survival time between the carcinomas with expres-
sion of CD133 (36.4 months) and those without (66.0
months) (Log rank = 53.80; P = 0.0001) (Figure 4). CD133
was an independent prognostic factor by multivariate
analysis (P = 0.0001).
The association between CD133 and Ki-67
Ki-67 was positive in 58.3% (196 out of 336) cases of gas-
tric adenocarcinoma and associated with clinicopatho-
logical features such as tumour size, invasive depth,
metastasis in regional lymph nodes, histological grade,
clinical stage and prognosis (Figure 5; Table 1). The posi-
tive correlation between CD133 and Ki-67 was found (r =
0.188, P = 0.001).
Discussion
Cancer stem cells, also known as tumour initiating cells,
refer to a small side population of tumour cells with
unlimited self-renewal activity and potentially promote
the formation of tumour, according to the cancer stem
cell (CSC) hypothesis that has emerged recently [28-32].
There is currently heightened interest in the utility of
using CD133 as a marker to identify the tumor stem cell
population for a variety of malignancies [3-5,8] Recently,
CD133 was found to be highly expressed in more or equal
to 50% of gastric, pancreatic and intrahepatic cholangio-
carcinomas [10]. Quantitative flow cytometric analysis
showed that a panel of established gastric cancer cell lines
expressed CD133 at levels higher than normal epithelial
cells. However, it has also been found that CD133 expres-
sion is not restricted to stem cells, and both CD133+ and
CD133- metastatic colon cancer cells initiate tumors
[33,34]. A murine anti-human CD133 antibody conju-
gated to a potent cytotoxic drug, monomethyl auristatin
F (MMAF), effectively inhibited the growth and induced
apoptosis of KATO III gastric cancer cells in vitro [10].
Therefore, anti-CD133 antibody-drug conjugates may
warrant further evaluation as a molecular therapeutic
strategy to eradicate CD133-positive tumour cells in gas-
tric cancer. CD133 expression as a prognostic marker has
been found in colorectal cancer [11-18] and brain
tumours [19-21], although it is still controversial for ovar-
ian cancer and non-small cell lung cancer. There are no
reports on the prognostic significance of CD133 expres-
Figure 1 Expression of CD133 protein in gastric adenocarcinoma. 
CD133 expressed positive in the membrane and cytoplasm of cancer 
cells in poorly-differentiated adenocarcinoma (grade 3). (CD133 ×400).
Figure 2 Expression of CD133 protein in gastric adenocarcinoma. 
CD133 predominantly localized in the membrane and cytoplasm 
around the lumen of cancerous glands in well-differentiated adenoo-
carcinoma (grade 1). (CD133 ×400).Zhao et al. BMC Cancer 2010, 10:218
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sion or correlation with Ki-67 in gastric cancer. In this
study the positive expression of CD133 is found in 57.4%
and is closely related to the worst prognosis of gastric
adenocarcinoma. Our results indicate that the expression
of CD133 may be involved in tumor size, invasive depth
and histological grade of gastric tumor, which are in
agreement with previous reports on colorectal cancer
[16,17]. In this research, the expression of CD133 posi-
tively correlates with the shorter survival time, suggesting
CD133-positive cells may contain more cancer stem-like
cells. Thus residual cancer stem-like cells after routine
therapy may lead to tumour recurrence and metastasis
through the self-renewal and multilineage differentiation
with agreement of cancer stem cell hypothesis [35,36]. It
implies that CD133 may be one of the specific molecular
markers in prognosis of gastric adenocarcinoma. The
results of our study, that Ki-67 expression corresponds
with tumor size, degree of differentiation, depth of inva-
sion, lymphatic metastasis, TNM staging and prognosis,
are associated with a previous report [37]. This research
Table 1: Relationship between CD133 or Ki-67 and clinicopathological features
Clinicopathological 
features
CD133 Probability Ki-67 Probability
+- +-
Ages
n≤40 16 18 0.434 20 14 0.291
40<n≥65 116 82 109 89
>65 61 43 67 37
Size
d<4 cm 30 47 0.0001 32 45 0.001
4 cm≤d<8 cm 117 84 121 80
d≥8 cm 46 12 43 15
Grade
1 7 10 0.032 6 11 0.007
23 0 3 5 3 0 3 5
3 156 98 160 94
Invasive depth
submucosa 4 19 0.0001 6 17 0.001
subserosa 47 56 52 51
visceral peritoneum 122 65 118 69
adjacent structures 20 3 20 3
Lymph nodes
N0 43 68 0.0001 44 67 0.0001
N1 78 50 77 51
N2 52 20 52 20
N3 20 5 23 2
Stage
I 1 9 4 70 . 0 0 0 12 0 4 6 0 . 0 0 0 1
II 38 39 40 37
III 98 49 96 51
IV 38 8 40 6
Five-year survival
A l i v e 4 4 8 20 . 0 0 0 14 6 6 0 0 . 0 0 0 1
Dead 149 61 150 60Zhao et al. BMC Cancer 2010, 10:218
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also shows that CD133 positively correlates with Ki-67,
implying higher putative proliferative activity in CD133-
positive cancer cells, which corresponds with the results
from Ieta, et al. [35]. Taken together, CD133 is highly
expressed in the cancer cells of gastric adenocarcinoma.
The combined detection of CD133 and Ki-67 expression,
to some extent, can reflect the biological behavior of gas-
tric cancer cells, thus guiding the choice of chemotherapy
and molecular targeting therapy.
Conclusions
It is suggested that CD133 may play an important role in
the evolution of gastric adenocarcinoma and it can be
considered as a potential marker for the prognosis in
patients with gastric adenocarcinoma.
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Figure 3 CD133 overexpressed in the membrane and cytoplasm 
of cancer cells located in invasive depth (CD133 ×400).
Figure 4 Kaplan-Meier survival analysis by CD133 status (n = 
336). The y-axis represents the percentage of patients; the x-axis, their 
survival in months. The green line represents CD133-positive patients 
with a trend of worse survival than the blue line representing CD133-
negative gastric carcinoma patients (Log rank = 53.80; P = 0.0001). 
Mean survival times were 36.3 months for the CD133- positive group 
and 66.0 months for the CD133-negative group.
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Figure 5 Ki-67 expressed in the nucleus of cancer cells located in 
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